NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations

Misregulation of hedgehog (Hh) signaling has been implicated in the pathogenesis of basal cell carcinoma (BCC) and medulloblastoma. Vismodegib, an orally bioavailable Hh signal pathway inhibitor targeting Smo, has been approved for the treatment of advanced BCC. However, acquired drug resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jie, Quan, Haitian, Xie, Chengying, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186412/
https://www.ncbi.nlm.nih.gov/pubmed/25505589
http://dx.doi.org/10.1002/prp2.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186412/
https://www.ncbi.nlm.nih.gov/pubmed/25505589
http://dx.doi.org/10.1002/prp2.43

Ejemplares similares